Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates.

Journal Article (Journal Article)

Memory T cells promote allograft rejection particularly in co-stimulation blockade-based immunosuppressive regimens. Here we show that the CD2-specific fusion protein alefacept (lymphocyte function-associated antigen-3-Ig; LFA -3-Ig) selectively eliminates memory T cells and, when combined with a co-stimulation blockade-based regimen using cytotoxic T lymphocyte antigen-4 (CTLA-4)-Ig, a CD80- and CD86-specific fusion protein, prevents renal allograft rejection and alloantibody formation in nonhuman primates. These results support the immediate translation of a regimen for the prevention of allograft rejection without the use of calcineurin inhibitors, steroids or pan-T cell depletion.

Full Text

Duke Authors

Cited Authors

  • Weaver, TA; Charafeddine, AH; Agarwal, A; Turner, AP; Russell, M; Leopardi, FV; Kampen, RL; Stempora, L; Song, M; Larsen, CP; Kirk, AD

Published Date

  • July 2009

Published In

Volume / Issue

  • 15 / 7

Start / End Page

  • 746 - 749

PubMed ID

  • 19584865

Pubmed Central ID

  • PMC2772128

Electronic International Standard Serial Number (EISSN)

  • 1546-170X

Digital Object Identifier (DOI)

  • 10.1038/nm.1993


  • eng

Conference Location

  • United States